Pharmaceuticals News and Research

RSS

IQWiG dossier assessment finds no added benefit of lixisenatide

Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.

3 Aug 2013

Atossa Genetics: Many American women still not aware of breast cancer risk

Virtually all American women are aware that the pink ribbon is the symbol of breast cancer awareness. Despite this near-universal recognition, it is still a sad fact that plenty of women do not truly appreciate the extent to which they are at risk for breast cancer.

3 Aug 2013

Added benefit of thyroid cancer drug vandetanib not proven

Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products.

3 Aug 2013

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine.

2 Aug 2013

New automated stainer for high throughput staining launched by Thermo Scientific

This new advanced automated stainer offers significant improvements in workflow optimization, particularly when multiple protocols are used. It has been intelligently designed to be easier to use than ever, with a new touch screen interface and intuitive software.

2 Aug 2013

Neuland Laboratories Q1 FY 2014 revenues decrease 4% to $20.27 million

Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients, complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the first quarter of fiscal year 2014, ended June 30, 2013.

2 Aug 2013

Keeping Alzheimer's disease in check

The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.

2 Aug 2013

Thermo Fisher Scientific opens cell culture DPM production site in Singapore

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it is expanding its global cell culture and bioprocessing capabilities by opening a new manufacturing plant in Singapore to produce dry powder media, a crucial cell culture raw material used to manufacture biologics, including vaccines, anti-cancer therapeutics, and others.

2 Aug 2013

New survey commissioned by PhRMA identifies America's top health priorities

A new survey commissioned by the Pharmaceutical Research and Manufacturers of America shows 86 percent of Americans believe developing cures for more forms of cancer should be one of the top national health priorities, followed by developing effective treatments for heart disease (78 percent) and more intensive medical care for seniors (76 percent).

2 Aug 2013

FDA promise to "reboot" antibiotic development rules to combat rise in resistance falls short

The rise of antibiotic resistance among hospital-acquired infections is greater than the Centers for Disease Control and Prevention found in its 2008 analysis, according to an ahead-of-print article in the journal, Antimicrobial Agents and Chemotherapy.

2 Aug 2013

Microbiologists identify staph-killing compound that may be effective for osteomyelitis

Osteomyelitis, a debilitating bone infection most frequently caused by Staphylococcus aureus ("staph") bacteria, is particularly challenging to treat.

2 Aug 2013

August edition of NPS RADAR includes reviews for new medicines listed on PBS

The 10th anniversary edition of NPS RADAR contains reviews for new medicines listed on the Pharmaceutical Benefits Scheme including rivaroxaban (Xarelto), rotigotine patches (Neupro) and mifepristone (Mifepristone Linepharma) followed by misoprostol (GyMiso).

1 Aug 2013

Viropharma announces financial results for second quarter of 2013

VIROPHARMA INCORPORATED (Nasdaq: VPHM) today announced financial results for the second quarter of 2013. Net sales were $104 million for the second quarter ended June 30, 2013 as compared to $95 million in the comparative period of 2012.

1 Aug 2013

BD reports quarterly revenues of $2.053 billion for third fiscal quarter

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.053 billion for the third fiscal quarter ended June 30, 2013, representing an increase of 3.6 percent from the prior-year period, or 5.1 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 1 Aug 2013

NCI experts suggest sweeping changes in approach to cancer detection, treatment

A group of experts at the National Cancer Institute is recommending sweeping changes in the approach to cancer detection and treatment, including dropping the word "cancer" completely from some common diagnoses.

1 Aug 2013

Study suggests silicon nanocrystals may be safe tool for diagnostic imaging in humans

Tiny silicon crystals caused no health problems in monkeys three months after large doses were injected, marking a step forward in the quest to bring such materials into clinics as biomedical imaging agents, according to a new study.

1 Aug 2013

New NIH projects to target Fragile X syndrome, nicotine addiction and AMD

The National Institutes of Health has launched three innovative projects that will focus on development of therapeutics for Fragile X syndrome, nicotine addiction, and age-related macular degeneration. These projects are funded through the NIH Blueprint Neurotherapeutics Network which provides access to a variety of drug development resources.

1 Aug 2013

Lupin gets tentative approval from FDA for Armodafinil Tablets, Doxycycline Capsules

elsPharma Major Lupin Limited announced that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration.

1 Aug 2013

SASB releases first set of provisional standards for industries in Health Care sector

The Sustainability Accounting Standards Board, a 501c3 non-profit organization that provides sustainability accounting standards for use by publicly listed corporations in the U.S., today released its first set of provisional standards for industries in the Health Care sector.

31 Jul 2013

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Pain is defined by the sufferer’s experience. Pain may be severe because it is intense, frequent or sustained, and because it is distressing. The severity of pain is not simply due to what is going on in the joint, but is also affected by how the body processes the pain signals, and the context in which it is experienced.

31 Jul 2013

Pharmaceuticals News and Research

IQWiG dossier assessment finds no added benefit of lixisenatide

Atossa Genetics: Many American women still not aware of breast cancer risk

Added benefit of thyroid cancer drug vandetanib not proven

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

New automated stainer for high throughput staining launched by Thermo Scientific

Neuland Laboratories Q1 FY 2014 revenues decrease 4% to $20.27 million

Keeping Alzheimer's disease in check

Thermo Fisher Scientific opens cell culture DPM production site in Singapore

New survey commissioned by PhRMA identifies America's top health priorities

FDA promise to "reboot" antibiotic development rules to combat rise in resistance falls short

Microbiologists identify staph-killing compound that may be effective for osteomyelitis

August edition of NPS RADAR includes reviews for new medicines listed on PBS

Viropharma announces financial results for second quarter of 2013

BD reports quarterly revenues of $2.053 billion for third fiscal quarter

NCI experts suggest sweeping changes in approach to cancer detection, treatment

Study suggests silicon nanocrystals may be safe tool for diagnostic imaging in humans

New NIH projects to target Fragile X syndrome, nicotine addiction and AMD

Lupin gets tentative approval from FDA for Armodafinil Tablets, Doxycycline Capsules

SASB releases first set of provisional standards for industries in Health Care sector

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence